Page 57 - Read Online

Morgan et al. HOX genes and the tumor microenvironment

41. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, progression. Cancers (Basel) 2014;6:1298-327.
Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten 54. Chambers AF, Matrisian LM. Changing views of the role of matrix
GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen- metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-70.
van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken 55. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion
JA. Detection of high-grade prostate cancer using a urinary molecular of matrix metalloproteinases and their inhibitors (tissue inhibitor of
biomarker-based risk score. Eur Urol 2016;70:740-8. metalloproteinases) by human prostate in explant cultures: reduced
42. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH. HOXB13 homeodomain tissue inhibitor of metalloproteinase secretion by malignant tissues.
protein suppresses the growth of prostate cancer cells by the negative Cancer Res 1993;53:4493-8.
regulation of T-cell factor 4. Cancer Res 2004;64:3046-51. 56. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S.
43. Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces Reduced angiogenesis and tumor progression in gelatinase A-deficient
growth suppression of prostate cancer cells as a repressor of hormone- mice. Cancer Res 1998;58:1048-51.
activated androgen receptor signaling. Cancer Res 2004;64:9185-92. 57. Pruett ND, Hajdu Z, Zhang J, Visconti RP, Kern MJ, Wellik
44. Kim YR, Oh KJ, Park RY, Xuan NT, Kang TW, Kwon DD, Choi C, DM, Majesky MW, Awgulewitsch A. Changing topographic Hox
Kim MS, Nam KI, Ahn KY, Jung C. HOXB13 promotes androgen expression in blood vessels results in regionally distinct vessel wall
independent growth of LNCaP prostate cancer cells by the activation remodeling. Biol Open 2012;1:430-5.
of E2F signaling. Mol Cancer 2010;9:124. 58. Care A, Felicetti F, Meccia E, Bottero L, Parenza M, Stoppacciaro A,
45. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe Peschle C, Colombo MP. HOXB7: a key factor for tumor-associated
WD, Wiley KE, Isaacs SD, Johng D, Wang Y, Bizon C, Yan G, angiogenic switch. Cancer Res 2001;61:6532-9.
Gielzak M, Partin AW, Shanmugam V, Izatt T, Sinari S, Craig DW, 59. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda
Zheng SL, Walsh PC, Montie JE, Xu J, Carpten JD, Isaacs WB, RP, Schwartz SA. Gene expression of angiogenic factors correlates
Cooney KA. Germline mutations in HOXB13 and prostate-cancer with metastatic potential of prostate cancer cells. Cancer Res
risk. N Engl J Med 2012;366:141-9. 2004;64:5311-21.
46. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, Cannon- 60. Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD,
Albright LA, Teerlink CC, Camp NJ, Johnson AM, Zuhlke KA, Chadha KC, Schwartz SA. Overexpression of MMP-9 contributes
Stanford JL, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Maier C, to invasiveness of prostate cancer cell line LNCaP. Immunol Invest
Luedeke M, Vogel W, Schleutker J, Wahlfors T, Tammela T, Schaid D, 2011;40:447-64.
McDonnell SK, DeRycke MS, Cancel-Tassin G, Cussenot O, Wiklund 61. Nalla AK, Gorantla B, Gondi CS, Lakka SS, Rao JS. Targeting MMP-
F, Grönberg H, Eeles R, Easton D, Kote-Jarai Z, Whittemore AS, Hsieh 9, uPAR, and cathepsin B inhibits invasion, migration and activates
CL, Giles GG, Hopper JL, Severi G, Catalona WJ, Mandal D, Ledet E, apoptosis in prostate cancer cells. Cancer Gene Ther 2010;17:599-613.
Foulkes WD, Hamel N, Mahle L, Moller P, Powell I, Bailey-Wilson 62. Mace KA, Hansen SL, Myers C, Young DM, Boudreau N. HOXA3
JE, Carpten JD, Seminara D, Cooney KA, Isaacs WB; International induces cell migration in endothelial and epithelial cells promoting
Consortium for Prostate Cancer Genetics. HOXB13 is a susceptibility angiogenesis and wound repair. J Cell Sci 2005;118:2567-77.
gene for prostate cancer: results from the International Consortium for 63. Wang H, Liu G, Shen D, Ye H, Huang J, Jiao L, Sun Y. HOXA1
Prostate Cancer Genetics (ICPCG). Hum Genet 2013;132:5-14. enhances the cell proliferation, invasion and metastasis of prostate
47. Lin X, Qu L, Chen Z, Xu C, Ye D, Shao Q, Wang X, Qi J, Chen Z, cancer cells. Oncol Rep 2015;34:1203-10.
Zhou F, Wang M, Wang Z, He D, Wu D, Gao X, Yuan J, Wang G, Xu 64. Li XY, Ota I, Yana I, Sabeh F, Weiss SJ. Molecular dissection of
Y, Wang G, Dong P, Jiao Y, Yang J, Ou-Yang J, Jiang H, Zhu Y, Ren the structural machinery underlying the tissue-invasive activity
S, Zhang Z, Yin C, Wu Q, Zheng Y, Turner AR, Tao S, Na R, Ding of membrane type-1 matrix metalloproteinase. Mol Biol Cell
Q, Lu D, Shi R, Sun J, Liu F, Zheng SL, Mo Z, Sun Y, Xu J. A novel 2008;19:3221-33.
germline mutation in HOXB13 is associated with prostate cancer risk 65. Jennbacken K, Gustavsson H, Welen K, Vallbo C, Damber JE. Prostate
in Chinese men. Prostate 2013;73:169-75. cancer progression into androgen independency is associated with
48. Cardoso M, Maia S, Paulo P, Teixeira MR. Oncogenic mechanisms alterations in cell adhesion and invasivity. Prostate 2006;66:1631-40.
of HOXB13 missense mutations in prostate carcinogenesis. 66. Wang X, Wilson MJ, Slaton JW, Sinha AA, Ewing SL, Pei D. Increased
Oncoscience 2016;3:288-96. aggressiveness of human prostate PC-3 tumor cells expressing cell
49. Kim YR, Kang TW, To PK, Xuan Nguyen NT, Cho YS, Jung C, surface localized membrane type-1 matrix metalloproteinase (MT1-
Kim MS. HOXB13-mediated suppression of p21WAF1/CIP1 MMP). J Androl 2009;30:259-74.
regulates JNK/c-Jun signaling in prostate cancer cells. Oncol Rep 67. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P,
2016;35:2011-6. Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella
50. Huang Q, Whitington T, Gao P, Lindberg JF, Yang Y, Sun J, Vaisanen RL, Fridman R, Cher ML. Prostate cancer-associated membrane
MR, Szulkin R, Annala M, Yan J, Egevad LA, Zhang K, Lin R, Jolma type 1-matrix metalloproteinase: a pivotal role in bone response and
A, Nykter M, Manninen A, Wiklund F, Vaarala MH, Visakorpi T, Xu intraosseous tumor growth. Am J Pathol 2007;170:2100-11.
J, Taipale J, Wei GH. A prostate cancer susceptibility allele at 6q22 68. Chen J, Wang Z, Xu D, Liu Y, Gao Y. Aquaporin 3 promotes prostate
increases RFX6 expression by modulating HOXB13 chromatin cancer cell motility and invasion via extracellular signal-regulated
binding. Nat Genet 2014;46:126-35. kinase 1/2-mediated matrix metalloproteinase-3 secretion. Mol Med
51. Kim IJ, Kang TW, Jeong T, Kim YR, Jung C. HOXB13 regulates Rep 2015;11:2882-8.
the prostate-derived Ets factor: implications for prostate cancer cell 69. Slavin S, Yeh CR, Da J, Yu S, Miyamoto H, Messing EM, Guancial
invasion. Int J Oncol 2014;45:869-76. E, Yeh S. Estrogen receptor alpha in cancer-associated fibroblasts
52. Kim YR, Kim IJ, Kang TW, Choi C, Kim KK, Kim MS, Nam KI, suppresses prostate cancer invasion via modulation of thrombospondin
Jung C. HOXB13 downregulates intracellular zinc and increases NF- 2 and matrix metalloproteinase 3. Carcinogenesis 2014;35:1301-9.
kappaB signaling to promote prostate cancer metastasis. Oncogene 70. Zhang L, Zhao L, Zhao D, Lin G, Guo B, Li Y, Liang Z, Zhao XJ,
2014;33:4558-67. Fang X. Inhibition of tumor growth and induction of apoptosis in
53. Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix prostate cancer cell lines by overexpression of tissue inhibitor of
metalloproteinases and their natural inhibitors in prostate cancer matrix metalloproteinase-3. Cancer Gene Ther 2010;17:171-9.
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 6, 2017 285